Revolution Drops a Bombshell

 

At the 2026 ASCO Annual Meeting, Revolution Medicines presented detailed data from the global Phase III clinical trial RASolute 302. The trial evaluated the oral RAS(ON) multi-selective inhibitor daraxonrasib as second-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

 

Compared to standard chemotherapy, daraxonrasib nearly doubled median overall survival (OS) and progression-free survival (PFS) in both populations, reducing the risk of death by 60% overall, with benefits that were both statistically and clinically significant.

 

• RAS G12-mutant population: daraxonrasib group median OS of 13.2 months (chemotherapy group 6.6 months), HR=0.40 (95% CI: 0.30–0.54); median PFS of 7.3 months (chemotherapy group 3.5 months), HR=0.45 (95% CI: 0.34–0.59).

• Intent-to-treat (ITT) population (including patients with or without identified tumor RAS mutations): median OS of 13.2 months (chemotherapy group 6.7 months), HR=0.40 (95% CI: 0.30–0.53); median PFS of 7.2 months (chemotherapy group 3.6 months), HR=0.49 (95% CI: 0.38–0.64).

 

When Revolution CEO Mark Goldsmith presented these figures on stage, the audience erupted in applause. It was the most sensational moment of this year's ASCO, with some attendees moved to tears.

 

Amidst this explosive news, another piece of information was quietly drowned out. In early June, Thomas Lampron, Vice President of Global Oncology Marketing at Merck & Co., quietly left his position and subsequently joined Revolution. The drama of this personnel move lies in the fact that just months earlier, Merck had been in acquisition negotiations with Revolution, which ultimately broke down due to valuation disagreements.

 

Lampron was a key driver behind Keytruda's rise to "blockbuster king." He led Keytruda's launch in the U.S. market and was deeply involved in the global expansion of over 40 indications.

 

Now, as Keytruda's patent cliff rapidly approaches, Merck is urgently seeking its next pillar product. Will the company it failed to acquire become a real threat to Merck's oncology business? And what waves will the "show-stopping" Revolution make in the oncology market?

 

TONACEA 01: An "Unprecedented" Breakthrough

 

The RAS gene family, containing HARS, KRAS, and NARS subtypes, is the most frequently mutated gene family in cancer. KRAS is the primary oncogenic subtype, most commonly found in lung, colorectal, and pancreatic cancers. In pancreatic cancer, KRAS mutations are present in up to 90% of cases.

 

Pancreatic cancer, known as the "king of cancers," is one of the most difficult to treat. The 5-year overall survival rate is below 5%, and median survival is less than 6 months. The daraxonrasib data mark the first time that any pancreatic cancer patients receiving a drug intervention in the second-line setting have had an average survival exceeding one year.

 

Dr. Rachna Shroff, Chief of Hematology/Oncology at the University of Arizona Cancer Center, called the data "unprecedented" and of great significance for pancreatic cancer patients. ASCO Chief Medical Officer Dr. Julie Gralow described it as a "grand slam."

 

Due to the lack of a clear binding pocket on the surface of the RAS protein, this target was long considered "undruggable." Amgen's Lumakras (sotorasib) and BMS's Krazati (adagrasib) are first-generation RAS inhibitors, but they only target the KRAS G12C subtype and act on the "OFF" conformation of RAS.

 

However, G12C mutations account for a very low proportion of PDAC. More importantly, PDAC is characterized by hyperactivation of the RAS(ON) signaling pathway, regardless of the presence of a mutant RAS allele. Consequently, the efficacy of first-generation drugs in PDAC has generally been poor.

 

In a Phase I/II trial evaluating sotorasib monotherapy for KRAS G12C-mutant advanced solid tumors, 38 PDAC patients received sotorasib. Among the 8 patients achieving objective responses, the median duration of response was 5.7 months. In the overall population, median PFS was 4.0 months, and median OS was 6.9 months.

 

Data from the Phase II KRYSTAL-1 study of adagrasib in the pancreatic cancer cohort showed that among 10 evaluable patients, the ORR was 50% (all partial responses, including one unconfirmed), with a median duration of response of 7.0 months. At a median follow-up of 8.1 months, median PFS was 6.6 months.

 

Daraxonrasib's approach is entirely different from first-generation drugs. It is an oral, RAS(ON) multi-selective, non-covalent inhibitor capable of targeting tumors driven by various common RAS mutations.

 

The RASolute 302 trial enrolled 500 patients with previously treated metastatic PDAC. The results showed significant benefits in both OS and PFS, along with substantial improvements in patient quality of life.

 

In the overall population, the median time to pain worsening was 9.2 months in the daraxonrasib group versus 3.8 months in the chemotherapy group; the median time to worsening of overall health status/quality of life was 5.7 months versus 2.6 months, respectively.

 

On safety, the incidence of adverse events (any grade) was 100% in the daraxonrasib group and 97.7% in the chemotherapy group; the incidence of grade 3 or higher adverse events was 61.8% and 69.6%, respectively. The incidence of treatment-related grade 3 or higher adverse events was 43.6% vs 57.5%; serious treatment-related adverse events occurred in 10.8% vs 18.7%; and the rate of discontinuation due to adverse events was 1.2% vs 11.2%.

 

Thus, while daraxonrasib-related adverse events are common, the rate of treatment interruption or discontinuation was significantly lower than with chemotherapy.

 

Revolution's Chief Development Officer, Alan Sandler, stated that these results validate the RAS(ON) inhibitor strategy but that the success of daraxonrasib in second-line PDAC is just the "tip of the iceberg." "Our plan is to start treatment earlier, even moving into potentially curable stages," he said.

 

Daraxonrasib is currently being evaluated in two additional Phase III trials, RASolute 303 and RASolve 301, assessing its efficacy in first-line PDAC and non-small cell lung cancer, respectively.

 

Truist Securities predicts that daraxonrasib could launch in the U.S. in the third quarter of 2026, potentially becoming the world's first approved pan-KRAS inhibitor.

 

TONACEA 02: Revolution's Journey – From Discard to Darling

 

Revolution Medicines, now with a market capitalization exceeding US$33 billion, stands firmly at the top of the RAS field and shone brightly at this year's ASCO. However, its development journey has been quite曲折.

 

Revolution was originally founded as Midasyn by professors Martin D. Burke, Michael Fischbach, and Kevan Shokat in collaboration with Third Rock Ventures.

Third Rock Ventures is a venture capital firm specializing in early-stage biotechnology investments, adept at identifying technologies with translational potential from academic research. Its classic investment portfolio includes Revolution, Bluebird Bio, Nurix Therapeutics, and Warp Drive Bio, which was later acquired by Revolution.

 

In 2015, Revolution completed a US$45 million Series A financing round led by Third Rock Ventures. At that time, Revolution was primarily focused on developing novel therapies from natural products, with an early pipeline centered on antifungal agents for drug-resistant infections.

 

But Revolution soon pivoted to oncology. At the outset of its transformation, its core asset was the SHP2 inhibitor RMC-4630.

 

In July 2018, Sanofi obtained exclusive global rights to RMC-4630 outside the U.S. for an upfront payment of US$50 million and up to US$500 million in milestones, with the two parties sharing profits on a 50/50 basis in the U.S. market.

 

In 2019, Amgen entered into a collaboration with Revolution to explore combination therapy with sotorasib and RMC-4630.

 

However, in December 2022, Sanofi terminated the collaboration, and Revolution regained all rights to RMC-4630. Subsequently, due to poor progress in the combination therapy, Amgen also withdrew from the collaboration.

 

By that time, however, Revolution's research in the RAS field had begun to show promise. Kevan Shokat, one of its co-founders, was a key driver in this direction.

 

In 2013, Kevan Shokat published a paper in Nature, considered one of the breakthrough studies in the field of RAS target discovery. His team discovered a series of compounds that specifically bind to the KRAS G12C mutant. Crystallographic studies revealed the existence of a "pocket" on the surface of the KRAS G12C mutant protein that could bind small molecules. After binding to this pocket, small-molecule compounds could "lock" the KRAS G12C mutant in an inactive conformation, providing a potential target for inhibiting KRAS activity.

 

In 2018, Revolution acquired Warp Drive Bio, gaining its SMART drug discovery platform. This platform utilizes unique molecular engagement mechanisms and molecular glue technology to target otherwise undruggable proteins. This acquisition provided the key technological foundation for Revolution's subsequent development of RAS(ON) inhibitors.

 

Building on this, Revolution developed a ternary complex compound platform, creating druggable pockets on the surface of targets lacking binding sites by inducing the formation of ternary complexes. Thus, Revolution established its RAS(ON) inhibitor strategy and became the first pharmaceutical company to successfully develop inhibitors selectively targeting the active state of RAS.

 

Based on this strategy, Revolution has built a relatively comprehensive pipeline matrix in the RAS field. Beyond daraxonrasib, the KRAS G12D inhibitor zoldonrasib (RMC-9805) has entered Phase III for first-line metastatic PDAC; the KRAS G12C inhibitor elironrasib (RMC-6291) and RMC-5127 targeting the G12V mutation are also in Phase II.

 

TONACEA 03: Merck's Regret

 

As its core pipelines advanced into later stages of development, Revolution's market value has risen. Currently, its market capitalization exceeds US$33 billion, surpassing even legacy biotech Biogen.

 

In early 2026, acquisition rumors began circulating. On January 7, The Wall Street Journal reported that AbbVie was in advanced discussions to acquire Revolution at a valuation potentially exceeding US$20 billion. The news sent Revolution's stock soaring 28% instantly. However, AbbVie quickly denied the rumors, stating it was "not in any negotiations with Revolution."

 

At that time, another MNC emerged as a potential buyer. According to the Financial Times, Merck & Co. was in discussions to acquire Revolution at a valuation between US$28 billion and US$32 billion. If completed, it would have been the largest M&A deal in biopharma since Pfizer's US$43 billion acquisition of Seagen in 2023.

 

Merck's sense of urgency stems from the approaching patent cliff for Keytruda. In 2025, the world's best-selling oncology drug contributed nearly half of Merck's revenue, with annual sales reaching US$31.6 billion. Keytruda's core patent expires in 2028.

 

In recent years, Merck has been continuously supplementing its pipeline through external M&A, seeking the next blockbuster to "succeed" Keytruda. In July 2025, it acquired Verona Pharma for approximately US$10 billion to enter the COPD space. In November of the same year, it acquired Cidara Therapeutics for US$9.2 billion to establish a presence in the influenza field. In March 2026, it acquired Terns Pharmaceuticals for US$6.7 billion to enter the hematologic oncology space.

 

Against this backdrop, the RAS target holds irresistible strategic value for Merck.

 

Approximately 23%-25% of malignant tumors carry KRAS mutations. According to DelveInsight analysis, the total market size for KRAS inhibitors in the seven major markets is expected to surge from US$526 million in 2025 to US$7.8 billion in 2034, a compound annual growth rate of 35%, making it one of the fastest-growing segments in the oncology market.

 

Some analysts predict that daraxonrasib alone could generate peak sales exceeding US$10 billion in pancreatic cancer.

 

For a "dominant force" in oncology like Merck, RAS is a target it cannot afford to miss. However, negotiations between Merck and Revolution ultimately broke down, reportedly due to disagreements over valuation.

 

In a dramatic turn, less than half a year later, Thomas Lampron, Vice President of Global Oncology Marketing at Merck, announced his departure, subsequently joining Revolution.

 

Lampron was a key driver behind Keytruda's ascent to "blockbuster king." He led Keytruda's launch in the U.S. market and was deeply involved in the global expansion of over 40 indications.

 

Additionally, Lampron facilitated Merck's collaboration with AstraZeneca on the PARP inhibitor Lynparza, which achieved global sales of US$3.28 billion in 2025, another blockbuster in the oncology field.

 

Lampron's accomplishments extend far beyond this. The global launch strategies for Merck's Alzheimer's drug Lenvima (in collaboration with Eisai), the TROP2 ADC Sac-TMT licensed from Kelun-Biotech, the LSD1-targeted inhibitor Bomedemstat acquired through Imago, and the reversible non-covalent BTK inhibitor Nemtabrutinib acquired through ArQule – all of these drugs bear Lampron's imprint.

 

One could say Lampron is a rare oncology commercialization expert possessing both strategic vision and executional capability. Not only does he excel at driving a drug from zero to the global market, but within a large pharma's complex product matrix, he can precisely allocate resources, drive cross-indication expansion, and integrate external collaborations. He is the core operator who propelled Merck's oncology business from a strong position to a dominant one.

 

Daraxonrasib has the potential not only to disrupt the current treatment landscape for pancreatic cancer but also to propel Revolution into the ranks of the top players in oncology.

 

Notably, at the beginning of the year, Revolution's market capitalization was only around US$16 billion. Based on its current valuation of US$33 billion, if an MNC were to acquire Revolution, the transaction price would likely need to double from the earlier rumored figures.

 

Will the rising star Revolution choose to change hands, or will it go further on its own? Will Merck pay a price for its hesitation? The ending of this story can only be told by time.

 

References:

• ASCO: Revolution Medicines confident in RAS leadership as rivals square up; FiercePharma

• 'Unprecedented' Revolution data point to paradigm shift in pancreatic cancer; BioPharma Dive

• New drug for pancreatic cancer achieves "grand slam": doubled survival in second-line treatment, improved quality of life; NEJM Medical Frontier

• ASCO finale king! Rejects $200 billion acquisition, market cap soars 300%, the strongest comeback story in pharma; E Drug Manager

• Merck's Keytruda driver jumps to KRAS star company; Drug Times

• 54 investments, 20 IPOs: Uncovering the secret of Third Rock's decades-long impact on U.S. biomedical industry; Sheng Hui

• 40 years of perseverance finally pays off: What breakthroughs lie behind conquering the famous "undruggable" target? WuXi AppTec

• Merck, out of reach?